Every day, over 54,500 people are diagnosed with cancer and more than 26,000 succumb. Pharma leaders are answering the call by increasing investments in cancer drug research and developing personalized treatments, along with early screening and early-stage drug interventions in curative settings. These range from small molecule targeted agents, immunotherapies, and antibody-drug conjugates (ADCs) to cell and gene therapies. In the past decade, over 100 new molecular entities have been approved by the FDA; unsurprisingly, today competition is fierce.
That puts renewed focus on oncologists. Oncologists are the key decision makers in oncology therapies; with therapeutic choices evolving rapidly, oncologists need to absorb lots of new information as they face increasingly complex decisions. A positive perception of and relationship with the manufacturer plays an important role in decision-making. Thus, understanding oncologists' perceptions is crucial for manufacturers to gauge their standing on various aspects of their relationships with oncologists and identify areas for improvement.
ZoomRx identifies manufacturers’ strengths, areas for improvement, and opportunities for deeper collaboration with the healthcare community, by combining HCPs’ ranking of oncology manufacturers, their pipeline, and their promoter scores.
Enter your information below to instantly access the full white paper:
